Therapeutic Drug Monitoring Market Was Valued USD 1.77 Billion In 2015 And Is Expected To Reach $3.37 Billion By 2024: Grand View Research, Inc.

Therapeutic drug monitoring market to reach $3.37 billion by
2024
“The global therapeutic drug monitoring market is expected to reach over USD 3.37
billion by 2024. The growing need to perform drug profiling for various medications,
such as anti-epileptics, immunosuppressants, and antibiotics, is one of the foremost
factors responsible for the market growth”
The global therapeutic drug monitoring market is expected to reach over USD
3.37 billion by 2024, according to a new report by Grand View Research, Inc. Recent
technological advancements in the Point-of-Care (PoC) devices hold considerable
transformative promises for the personalized predictive and preventive medicine.
Therapeutic Drug Monitoring (TDM) forms a foundational part to the devising of
personalized treatment plans for patients; and the advent of PoC diagnostic devices
that yield quantitative measurements of the drug concentration plays a pivotal role in
supporting the development of the precision medicine field in the healthcare sector.
However, the broad application of the PoC devices for patient monitoring is still lagging
behind. The presence of this untapped opportunity is one of the high impact rendering
drivers for the market growth.
Follow Us:
Detailed Research Report available at:
http://www.grandviewresearch.com/industry-analysis/therapeutic-drugmonitoring-market
The employment of continuous therapeutic drug and metabolite monitoring in the early
phase of the medication regimen, administered post-organ transplantation, forms a
major application in the areas of critical care medicine and organ transplantation, which
is expected to propel the growth of the therapeutic drug monitoring market over the
forecast period. In addition, the imposing burden of diseases, such as epilepsy and
cancer, the rising government initiatives, and the presence of high-unmet needs are
some of the crucial determinants expected to further favor the emergence of this
market.
Further key findings from the study suggest:

The consumables segment covered over 65% of the market share in 2015 as a
consequence of the extensive requirement of the consumables in the research
laboratories and due to the repeat purchase of the kits and reagents.

The immunoassay segment held the largest market share in 2015. The presence
of several commercially available immunoassays combined with their associated
benefits including the cost effectiveness and easy-to-handle nature of the
products are the key drivers for the growth of this segment.

The proteomics category is expected to be the fastest growing technology
segment due to the advent of various proteomic technologies, such as isotopecoded affinity tags, next generation sequencing, and protein microarray platforms
that enable rapid mining of the proteome.

The hospital is the largest end-use segment with a share of over 60% in 2015. In
larger hospitals, various underlying technologies are employed to perform
Follow Us:
immunoassays; these comprise chemiluminescence, nephelometry, colorimetry,
and fluorescence, which are available for the testing of a wide ranging drug
panel.

The drug monitoring for the immunosuppressants is one of the fastest growing
application segments owing to the introduction of novel TDM point-of-care testing
devices
for
the
evaluation
of
the
concentration
of
administered
immunosuppressants and the complementary metabolites, in order to achieve a
prominent therapeutic effect while preventing drug toxicity events in patients that
have undergone transplantations.

In 2015, North America was the highest revenue generating region with revenue
generated over USD 900 million. The rising number of R&D activities coupled
with the high awareness about personalized therapy is the major determining
factor for the large share captured by the North America region.

Few of the leading market players are Roche Diagnostics, Siemens Healthcare
GmbH, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman
Coulter, Inc., Abbott Laboratories, Inc., Agilent Technologies, Inc., bioMérieux,
Inc., and Alere, Inc. The persistent R&D efforts are being undertaken along with
numerous other strategic endeavors being adopted by the market players with
the objective of enhancing the present drug monitoring practices and to develop
novel technologies.
Read our blog on healthcare industry:
http://www.grandviewresearch.com/blogs/healthcare
Table of content of global therapeutic drug monitoring market research report:
Chapter 1.Methodology And Scope
Follow Us:
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Therapeutic drug monitoring market - Industry Snapshot and Key
Buying Criteria, 2013 - 2024
Chapter 3. Therapeutic Drug Monitoring Market, Industry Outlook
3.1. Market segmentation
3.2. Market size and growth prospects
3.3. Therapeutic drug monitoring market: Market dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key opportunities prioritized
3.5. Industry Analysis - Porter's
3.6. Therapeutic drug monitoring market PESTEL analysis, 2015
Chapter 4. Therapeutic Drug Monitoring Market, Product Outlook
4.1. Therapeutic drug monitoring market share by product, 2015 & 2024
Follow Us:
4.2. Consumables
4.2.1. Consumables market estimates and forecasts, 2013 - 2024 (USD
Million)
4.3. Equipment
4.3.1. Equipment market estimates and forecasts, 2013 - 2024 (USD
Million)
4.4. Others
4.4.1. Others market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 5. Therapeutic Drug Monitoring Market, Technology Outlook
5.1. Therapeutic drug monitoring market share by technology, 2015 & 2024
5.2. Immunoassays
5.2.1. Immunoassays market estimates and forecasts, 2013 - 2024 (USD
Million)
5.3. Proteomic technologies
5.3.1. Proteomic technologies market estimates and forecasts, 2013 2024 (USD Million)
5.4. Others
5.4.1. Others market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 6. Therapeutic Drug Monitoring Market, Drug Class Outlook
Follow Us:
6.1. Therapeutic drug monitoring market share by drug class, 2015 & 2024
6.2. Anti - epileptics
6.2.1. Anti - epileptic market estimates and forecasts, 2013 - 2024 (USD
Million)
6.3. Antibiotics
6.3.1. Antibiotics market estimates and forecasts, 2013 - 2024 (USD
Million)
6.4. Immunosuppressants
6.4.1. Immunosuppressants market estimates and forecasts, 2013 - 2024
(USD Million)
6.5. Psychoactive drugs
6.5.1. Psychoactive drugs market estimates and forecasts, 2013 - 2024
(USD Million)
6.6. Anti-arrhythmic drugs
6.6.1. Anti-arrhythmic drugs market estimates and forecasts, 2013 - 2024
(USD Million)
6.7. Others
6.7.1. Others drug market estimates and forecasts, 2013 - 2024 (USD
Million)
Follow Us:
Chapter 7. Therapeutic Drug Monitoring Market, End - use Outlook
7.1. Therapeutic drug monitoring market share by end - use, 2015 & 2024
7.2. Hospital labs
7.2.1. Hospital labs market estimates and forecasts, 2013 - 2024 (USD
Million)
7.3. Private labs
7.3.1. Private labs market estimates and forecasts, 2013 - 2024 (USD
Million)
7.4. Others
7.4.1. Others market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 8. Drug Monitoring Market Regional Outlook
8.1. Therapeutic drug monitoring market share by region, 2015 & 2024
8.2. North America
8.2.1. North America market estimates and forecasts, by product, 2013 2024 (USD Million)
8.2.1.1. U.S. market estimates and forecasts
8.2.1.2. Canada market estimates and forecasts
8.2.2. North America market estimates and forecasts, by technology
type, 2013 - 2024 (USD Million)
Follow Us:
8.2.2.1. U.S. market estimates and forecasts
8.2.2.2. Canada market estimates and forecasts
8.2.3. North America market estimates and forecasts, by drug class,
2013 - 2024 (USD Million)
8.2.3.1. U.S. market estimates and forecasts
8.2.3.2. Canada market estimates and forecasts
8.2.4. North America market estimates and forecasts, by end - use type,
2013 - 2024 (USD Million)
8.2.4.1. U.S. market estimates and forecasts
8.2.4.2. Canada market estimates and forecasts
8.3. Europe
8.3.1. Europe market estimates and forecasts, by product , 2013 - 2024
(USD Million)
8.3.1.1. UK market estimates and forecasts
8.3.1.2. Germany market estimates and forecasts
8.3.2. Europe market estimates and forecasts, by technology, 2013 2024 (USD Million)
8.3.2.1. UK market estimates and forecasts
8.3.2.2. Germany market estimates and forecasts
Follow Us:
8.3.3. Europe market estimates and forecasts, by drug class, 2013 2024 (USD Million)
8.3.3.1. UK market estimates and forecasts
8.3.3.2. Germany market estimates and forecasts
8.3.4. Europe market estimates and forecasts, by end - use, 2013 - 2024
(USD Million)
8.3.4.1. UK market estimates and forecasts
8.3.4.2. Germany market estimates and forecasts
8.4. Asia Pacific
8.4.1. Asia Pacific market estimates and forecasts, by product, 2013 2024 (USD Million)
8.4.1.1. Japan market estimates and forecasts
8.4.1.2. China market estimates and forecasts
8.4.2. Asia Pacific market estimates and forecasts, by technology, 2013 2024 (USD Million)
8.4.2.1. Japan market estimates and forecasts
8.4.2.2. China market estimates and forecasts
8.4.3. Asia Pacific market estimates and forecasts, by drug class, 2013 2024 (USD Million)
Follow Us:
8.4.3.1. Japan market estimates and forecasts
8.4.3.2. China market estimates and forecasts
8.4.4. Asia Pacific market estimates and forecasts, by end - use , 2013 2024 (USD Million)
8.4.4.1. Japan market estimates and forecasts
8.4.4.2. China market estimates and forecasts
8.5. Latin America
8.5.1. Latin America market estimates and forecasts, by product, 2013 2024 (USD Million)
8.5.1.1. Brazil market estimates and forecasts
8.5.2. Latin America market estimates and forecasts, by technology,
2013 - 2024 (USD Million)
8.5.2.1. Brazil market estimates and forecasts
8.5.3. Latin America market estimates and forecasts, by drug class, 2013
- 2024 (USD Million)
8.5.3.1. Brazil market estimates and forecasts
8.5.4. Latin America market estimates and forecasts, by end - use, 2013
- 2024 (USD Million)
8.5.4.1. Brazil market estimates and forecasts
Follow Us:
8.6. MEA
8.6.1. MEA market estimates and forecasts, by product , 2013 - 2024
(USD Million)
8.6.1.1. South Africa market estimates and forecast
8.6.2. MEA market estimates and forecasts, by technology, 2013 - 2024
(USD Million)
8.6.2.1. South Africa market estimates and forecast
8.6.3. MEA market estimates and forecasts, by drug class, 2013 - 2024
(USD Million)
8.6.3.1. South Africa market estimates and forecast
8.6.4. MEA market estimates and forecasts, by end - use, 2013 - 2024
(USD Million)
8.6.4.1. South Africa market estimates and forecast
Chapter 9. Competitive Landscape
9.1. Roche Diagnostics
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiatives
Follow Us:
9.2. biomérieux, Inc.
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Strategic Initiatives
9.3. Abbott Laboratories, Inc.
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Strategic Initiatives
9.4. Danaher Corporation
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Strategic Initiatives
9.5. Alere, Inc.
9.5.1. Company Overview
Follow Us:
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Strategic Initiatives
9.6. Agilent Technologies, Inc.
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Strategic Initiatives
9.7. Thermo Fisher Scientific, Inc.
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Strategic Initiatives
9.8. Siemens Healthcare GmbH
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
Follow Us:
9.8.4. Strategic Initiatives
9.9. Bio-Rad Laboratories, Inc.
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Strategic Initiatives
About Grand View Research, Inc.:
Grand View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The company
provides syndicated research reports, customized research reports, and consulting
services. To help clients make informed business decisions, the company offers
market intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
Web – http://www.grandviewresearch.com/
Follow Us:

The global therapeutic drug monitoring market is expected to reach over USD 3.37 billion by 2024, according to a new report by Grand View Research, Inc. Recent technological advancements in the Point-of-Care (PoC) devices hold considerable transformative promises for the personalized predictive and preventive medicine. Therapeutic Drug Monitoring (TDM) forms a foundational part to the devising of personalized treatment plans for patients; and the advent of PoC diagnostic devices that yield quantitative measurements of the drug concentration plays a pivotal role in supporting the development of the precision medicine field in the healthcare sector. Click here - http://www.grandviewresearch.com/industry-analysis/therapeutic-drug-monitoring-market

Download Report